Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 11, 2018* Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL
-
Nov 8, 2018Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m., ET
-
Nov 7, 2018* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)
-
Oct 23, 2018- Top-line data from the "PULSE" clinical trial expected in the second quarter of 2019
-
Oct 19, 2018-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype
-
Oct 16, 2018- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery
-
Sep 28, 2018* Libtayo is the third anti-PD-1 approved in the U.S.
-
Sep 12, 2018* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy
-
Sep 5, 2018Industry executive adds considerable financial expertise as audit committee chairperson
-
Sep 4, 2018
-
Sep 3, 2018- First therapeutic approved for the treatment of aTTP, a rare blood-clotting disorder
-
Jul 31, 2018- Provention strengthens its strategic platform in type 1 diabetes (T1D) interception and prevention
-
Jul 30, 2018Nearly 70 million doses to be manufactured this season
-
Jul 2, 2018- Company invests €66 million in Chengdu, Sichuan province, China